Skip to Content
Merck
  • Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.

Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.

Singapore medical journal (2012-12-27)
Ling Zhi Heng, Yujia Chen, Thiam Chye Tan
ABSTRACT

Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.

MATERIALS
Product Number
Brand
Product Description

USP
Butoconazole nitrate, United States Pharmacopeia (USP) Reference Standard
Pricing and availability is not currently available.